CRISPR Therapeutics (NASDAQ:CRSP) Earns “Market Outperform” Rating from JMP Securities
JMP Securities restated their market outperform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note published on Tuesday, Benzinga reports. The brokerage currently has a $74.00 price target on the stock. Other analysts have also recently issued research reports about the company. Royal Bank of Canada dropped their target price […]
More Stories
Sysco Co. (NYSE:SYY) Shares Purchased by Leelyn Smith LLC
Leelyn Smith LLC boosted its stake in Sysco Co. (NYSE:SYY – Free Report) by 5.0% in the 3rd quarter, according...
Stonebrook Private Inc. Lowers Position in Johnson & Johnson (NYSE:JNJ)
Stonebrook Private Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.5% during the 3rd quarter,...
49 Wealth Management LLC Grows Stock Position in Pfizer Inc. (NYSE:PFE)
49 Wealth Management LLC increased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 7.4% in the 3rd quarter,...
Pitcairn Co. Has $2.91 Million Stock Holdings in NextEra Energy, Inc. (NYSE:NEE)
Pitcairn Co. cut its position in shares of NextEra Energy, Inc. (NYSE:NEE – Free Report) by 3.2% during the third...
Meridian Wealth Management LLC Makes New $1.65 Million Investment in The Walt Disney Company (NYSE:DIS)
Meridian Wealth Management LLC acquired a new position in shares of The Walt Disney Company (NYSE:DIS – Free Report) during...
NextEra Energy, Inc. (NYSE:NEE) Shares Sold by Hamilton Point Investment Advisors LLC
Hamilton Point Investment Advisors LLC trimmed its holdings in NextEra Energy, Inc. (NYSE:NEE – Free Report) by 0.6% in the...